Recent discussions on X about CalciMedica, Inc. (CALC) have centered around the biotech company's stock performance and potential catalysts. Many users are speculating on upcoming clinical trial results, with some expressing optimism about the company's pipeline in acute inflammatory conditions. The chatter reflects a mix of curiosity and cautious hope as investors await concrete updates.
Additionally, there’s been notable attention on CALC’s price volatility, with some on X pointing to recent fluctuations as a sign of growing interest from retail traders. Discussions often highlight the stock’s low market cap as a point of intrigue, though opinions differ on the risks tied to its early-stage developments. This ongoing dialogue keeps the ticker in focus for those tracking small-cap biotech plays.
Note: This discussion summary was generated from an AI condensation of post data.
CalciMedica, Inc. Insider Trading Activity
CalciMedica, Inc. insiders have traded $CALC stock on the open market 12 times in the past 6 months. Of those trades, 12 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $CALC stock by insiders over the last 6 months:
- ERIC W ROBERTS (CHIEF BUSINESS OFFICER) has made 7 purchases buying 33,100 shares for an estimated $62,871 and 0 sales.
- ROBERT N WILSON purchased 4,500 shares for an estimated $12,915
- A. RACHEL LEHENY (CHIEF EXECUTIVE OFFICER) purchased 2,500 shares for an estimated $6,175
- STEPHEN BARDIN (Chief Financial Officer) has made 2 purchases buying 3,000 shares for an estimated $4,695 and 0 sales.
- KENNETH A. STAUDERMAN (Chief Scientific Officer) purchased 1,000 shares for an estimated $1,850
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
CalciMedica, Inc. Hedge Fund Activity
We have seen 11 institutional investors add shares of CalciMedica, Inc. stock to their portfolio, and 9 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ALYESKA INVESTMENT GROUP, L.P. removed 372,256 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $711,008
- STONEPINE CAPITAL MANAGEMENT, LLC removed 101,422 shares (-21.6%) from their portfolio in Q1 2025, for an estimated $193,716
- WEALTHEDGE INVESTMENT ADVISORS, LLC added 80,472 shares (+289.3%) to their portfolio in Q1 2025, for an estimated $153,701
- PVG ASSET MANAGEMENT CORP added 30,385 shares (+inf%) to their portfolio in Q1 2025, for an estimated $58,035
- CAMBRIDGE INVESTMENT RESEARCH ADVISORS, INC. added 23,539 shares (+inf%) to their portfolio in Q1 2025, for an estimated $44,959
- 180 WEALTH ADVISORS, LLC added 16,400 shares (+inf%) to their portfolio in Q1 2025, for an estimated $31,324
- FIRST MANHATTAN CO. LLC. added 13,226 shares (+inf%) to their portfolio in Q1 2025, for an estimated $25,261
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
CalciMedica, Inc. Analyst Ratings
Wall Street analysts have issued reports on $CALC in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 05/15/2025
To track analyst ratings and price targets for CalciMedica, Inc., check out Quiver Quantitative's $CALC forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
